Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US9956166B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2014 |
| Grant date | May 1, 2018 |
| Priority date | — |
| Expiry date | Nov 9, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/357
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.